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ABBREVIATION 
 
ITP   Immune (Idiopathic) Thrombocytopenic Purpura 
H.pylori  Helicobacter pylori 
HIV   Human Immunodeficiency Virus 
SLE   Systemic Lupus Erythematosus 
TTP   Thrombotic Thrombocytopenic Purpura 
HIT   Heparin Induced Thrombocytopenia. 
WBC   White Blood Cell 
TLC   Total Leucocyte Count 
RBC   Red Blood Cell 
DIC   Disseminated Intravascular Coagulation 
MAHA  Microangiopathic Hemolytic Anemia 
HCV   Hepatitis C Virus 
LDH   Lactate Dehydrogenase 
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ESR   Erythrocyte Sedimentation Rate 
CRP   C-Reactive Protein 
PCR   Polymerase Chain Reaction 
CMV   Cytomegalovirus 
EBV   Epstein Barr Virus 
MDS   Myelodysplastic syndrome 
TRA   Thrombopoetin Receptor Agonists 
GERD  Gastro esophageal Reflux Disease 
PPI's   Proton Pump Inhibitors 
RUT   Rapid Urease Test 
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INTRODUCTION 
Immune thrombocytopenic purpura (ITP) also known as idiopathic 
thrombocytopenic purpura, is an acquired disease of adults and children 
which is immune mediated and is characterized by transient or persistent 
decrease of the platelet count. The risk of bleeding increases depending upon 
the degree of thrombocytopenia. When ITP occurs in the absence of an 
evident predisposing etiology it is known as primary ITP. and when it occurs 
secondary to an identifiable cause it is known as secondary ITP. Pseudo 
thrombocytopenia should also be ruled out.  
Helicobacter pylori is an ubiquitous gram positive bacterium which was 
initially discovered in 1982. It colonizes the stomach of about half of the 
world’s human population throughout their lifetimes. H.pylori has been 
clearly recognized as the main cause of gastritis and most cases of peptic 
ulcer .It also plays a role in the pathogenesis of gastric adenocarcinoma and 
mucosa associated lymphoid tissue (MALT) lymphoma It has also been 
implicated in the pathogenesis of some autoimmune diseases such as 
rheumatoid arthritis, autoimmune thyroid disease and ITP. Relevant to this 
Gasbarrini et al recently conducted a study and showed a high prevalence of 
H.pylori infection in patients with ITP and also reported a good response to 
bacterium eradication in most of the cases.  
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The relationship between H.pylori and ITP was initially described in 1998 in 
an Italian study. However discrepant reports have been produced by 
subsequent studies. In countries like Japan and Italy where the prevalence of 
H.pylori is high, the association between H.pylori and ITP was more 
frequent that is 70% and 50% respectively. Whereas in United States where 
the incidence of H.pylori is low the association was only 22%. Thus H.pylori 
prevalence in ITP patients mirrored the prevalence of H.pylori in the general 
population. However studies from France and Spain where the prevalence of 
H.pylori was high , did not show significant improvements in platelet count 
after eradication therapy. 
Hence the association of H.pylori and ITP is still controversial. It is still not 
clear if H.pylori should be implicated as a secondary cause of ITP or it is 
just an alternative, additional or incidental finding in patients with ITP. All 
these possibilities have been suggested by different studies. In this study we 
aim to find the prevalence of H.pylori in ITP patients in our set up. 
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RESEARCH QUESTIONS: 
1. Is there an association between H. pylori and chronic ITP? 
2. Should patients with ITP be routinely screened and treated for H. 
pylori? 
3. Does prevalence of H. pylori in ITP reflect prevalence of H. pylori in 
the general population? 
4. Relation between H. pylori infection and age and H. pylori infection 
and dyspepsia symptoms? 
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AIMS AND OBJECTIVES 
 To study the association between immune thrombocytopenic Purpura 
and Helicobacter pylori infection. 
 To determine the prevalence of Helicobacter pylori infection in Indian 
patients with ITP. 
 To evaluate if H. Pylori infected patients with ITP could be identified 
by symptoms referable to the GI tract. 
 To study the clinical profile of ITP patients.  
14 
 
REVIEW OF LITERATURE 
IMMUNE THROBOCYTOPENIC PURPURA 
DEFINITION: 
ITP is an acquired autoimmune syndrome in which antibody (which are 
directed against the platelet antigens) and cell mediated destruction of 
platelets and suppression of platelet production causes the platelet count to 
drop less than 1,00,000 cells/cubic mm and predisposes to bleeding 
depending upon the degree of thrombocytopenia.
2
 It is a benign disorder. 
ITP in children is usually an acute and self limiting condition. 
Phases of ITP
 (3)
:
 
1. Newly diagnosed – diagnosis within 3 months of presentation. 
2. Persistent ITP – thrombocytopenia lasts for > 3 months but resolves by 12 
months. Includes patients who do not have spontaneous remission or patients 
who are not able to maintain complete response once they are off treatment. 
3. Chronic ITP – thrombocytopenia lasts for > 12 months and requires 
continuous management. 
4. Severe ITP: the patient presents with bleeding symptoms that mandates 
treatment or new bleeding symptoms occur which needs additional 
15 
 
therapeutic intervention in the form of increased dose of the drug or a 
platelet enhancing agent. 
The bone marrow may show normal or increased megakaryocytosis in 
patients with persistent and chronic ITP. Bone marrow is usually done in 
patients > 60 years of age to rule out myelodysplasia. 
ITP is a heterogeneous group of disorder in which there is autoimmune 
mediated destruction of platelet and impaired thrombopoiesis and this 
predisposes to bleeding. 
INCIDENCE AND DEMOGRAPHICS
4
:
 
According to the UK health registry the incidence of adult onset ITP ranges 
from 1.6 to 3.9 per 1, 00,000 persons per year. The prevalence ranges from 
9.5 to 23.6 per 1,00,000 persons. Initially adult onset ITP was believed to be 
a disease of young women, but recent studies have also shown an increased 
prevalence among older individuals. Males and females are equally affected 
in older age group whereas a female preponderance is seen among young 
adults. 
ETIOLOGY
5
:
 
Based on etiology ITP is classified as given below: 
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1. Primary ITP: Occurs in the absence of a definitive predisposing etiology 
2. Secondary ITP 
The initial step in the evaluation of patients with ITP is to rule out the 
secondary causes of ITP. 
Secondary causes of ITP: 
1. Pseudo thrombocytopenia 
2. Drug induced thrombocytopenia 
3. HIV infection 
4. Hepatitis C virus infection 
5. SLE 
6. Lymph proliferative disorders 
7. Myelodysplasia 
8. TTP 
9. Congenital/hereditary thrombocytopenia 
10. HIT (heparin induced thrombocytopenia and thrombosis) 
11. H.pylori 
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In some patients H.pylori eradication corrects the thrombocytopenia and is 
considered as an alternative diagnosis. Whereas in some patients it is an 
additional disorder which worsens thrombocytopenia. In another group of 
patients it has no effect on the platelet counts and is considered as an 
incidental finding.
5 
Some rare causes of secondary ITP includes fetal and neonatal alloimmune 
thrombocytopenic purpura and post transfusion purpura. 
PATHOGENESIS: 
Life span of platelet is reduced due to antibody mediated lysis by tissue 
macrophages. There is suppression of megakaryopoeisis and megakaryocyte 
apoptosis. Lysis of platelet occurs due to direct peroxide injury. Immune 
mediated suppression of megakaryocyte and platelet development. T-cell 
mediated platelet destruction also occurs. There is also direct bone marrow 
suppression. 
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NON- AUTOIMMUNE CAUSES OF THROMBOCYTOPENIA IN 
ADULTS:
4 
1 Pseudo thrombocytopenia 
2. Disorders of decreased platelet production: it includes viral infections, 
chemotherapy, radiotherapy, ethanol toxicity, congenital thrombocytopenia, 
folate or vitamin B12 deficiency, bone marrow disorders like MDS, 
myelofibrosis, and leukemia. 
3. Disorders of decreased platelet survival:  drugs like quinine and heparin, 
DIC, HUS, TTP, cardiopulmonary bypass, post transfusion purpura 
4. Dilutional thrombocytopenia 
5. Splenic sequestration: secondary to portal hypertension and infiltrative 
diseases of spleen. 
DIAGNOSIS: 
Primary ITP is a diagnosis of exclusion 
HISTORY AND PHYSICAL EXAMINATION: 
The clinical features are related to the platelet counts. Most of the patients 
present with mucocutaneous bleeding like bruising, gum bleeding, petechiae, 
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nose bleeds, heavy menses, hematuria, etc. Petechiae indicate a reduction of 
platelet number rather than a platelet dysfunction. Petechiae usually occur 
over areas of increased venous pressure so in ambulatory patients it is 
mainly seen over the ankles. Increased risk of life threatening hemorrhage in 
a thrombocytopenic patient is indicated by wet purpura that is blood blisters 
in buccal mucosa and retinal hemmorrhages.
1 
Symptoms pertaining to other diagnosis like antecedent viral infection, 
weight loss, fatigue, rash, joint swelling, lymph node enlargement, headache 
, personal history of autoimmune diseases etc. Family history of bleeding 
disorders (hemophilia, von Willibrand’s disease), autoimmune diseases, 
immunodeficiencies or bone marrow failure syndromes should be ruled out. 
Assess abdomen for hepatomegaly and splenomegaly and mental status 
changes to rule out intracranial bleed. Look for ecchymosis and unequal 
pupils. Examine the testicles for males as thrombocytopenia may be the 
presenting symptom of leukemia. 
LABORATORY EVALUATION: 
Complete blood count, reticulocyte count 
Peripheral smear study 
Quantitative immunoglobulin (IgG, IgM, IgA) 
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Bone marrow examination (in selected patients especially when leukemia or 
myelodysplasia is considered) 
Blood grouping and typing (to administer immunoglobulin) 
Direct Coomb’s test (if patient has concurrent anemia) 
HIV, HCV 
LDH, uric acid, ESR, CRP 
Glycoprotein specific antibodies and antiphospholipid antibodies 
Anti-thyroid antibodies and thyroid function 
Antinuclear antibody  
Serum protein electrophoresis 
PCR for parvo virus, CMV, EBV. 
Stool antigen test or urea breath test for H. pylori in high prevalent areas 
 Tests of unproven benefit include 
thrombopoietin, reticulated platelets, platelet survival study, bleeding time 
and serum complement. Coombs test is done to diagnose Evans syndrome 
which includes autoimmune hemolytic anemia and ITP. 
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MANAGEMENT: 
Treatment should be individualized. Treatment depends mainly on the 
patients age and the disease severity because as the age increases the risk of 
bleeding and fatality increases. The primary goal is to keep platelet counts > 
30,000/cu mm while minimizing toxicity; as there no increased mortality if 
platelets are > 30,000/cu mm. This is based on the assumption that: 
1) Platelet count is a reliable surrogate marker of bleeding risk 
2) Natural history of primary ITP is not altered by medical therapy 
3) The burden of disease and its impact in quality of life are 
adequately captured by bleeding and drug toxicity 
When thrombocytopenia occurs secondary to a medical condition treatment 
should be targeted to correct the underlying disorder. Drugs used to treat ITP 
either increase the production of platelet, or decrease the production of 
antibodies or decrease the uptake of antibody coated platelet by the 
reticuloendothelial system. 
CRITERIA FOR TREATMENT: 
1) Active bleeding with any platelet count includes intracranial bleed, 
hematuria, epistaxis, menorrhagia, mucosal bleeding. 
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2) Platelet count < 10,000 
3) Platelet count < 30,000 if the patient has  any of the following 
including platelet dysfunction, surgery, trauma, use of 
anticoagulants , lifestyle changes with predisposition to injury.
5 
TARGET PLATELET COUNT IN ADULT ITP PATIENTS DURING 
SURGERY:
5 
SURGERY RECOMMENDED PLATELET 
COUNT 
Major neurosurgery ≥1,00,000 
Major surgery ≥80,000 
Minor surgery ≥50,000 
Complex dental extraction ≥50,000 
Regional dental block ≥30,000 
Simple dental procedure ≥30,000 
Dental prophylaxis (scaling, 
deep cleaning ) 
≥20,000 
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HOSPITALISATION AND EMERGENCY THERAPY: 
Patients with severe major bleeding and platelet <10,000 are hospitalized 
immediately and given platelet transfusions 15 ml/kg until the bleeding stops 
and the platelet count exceeds 30,000cells/cu mm. Along with this 
methylprednisolone 30mg/kg is given intravenously over 20 minutes and 
intravenous  immunoglobulin 1g/kg upto 5 doses may be given. The patient 
has to be pre-medicated with acetaminophen and diphenhydramine one hour 
prior to administration of immunoglobulin. Epsilon aminocaproic acid or 
tranexamic acid can be used to control epistaxis and oral bleed. Fibrin glue 
and topical thrombin for dental extractions and management of menorrhagia 
with progestational agents. Patients with intracranial bleed and who require 
immediate hemostatic response maybe treated with recombinant factor seven 
a
4
 if they do not respond to other modalities of treatment. It is important to 
stop drugs which cause platelet dysfunction and increase the risk of bleeding 
and to control blood pressure. Re-check platelet after 24 hours, if it is 
>20,000 repeat after 7 days or consider re-treatment. If anti-Rh( D) is given 
do urine analysis, LDH and bilirubin to asses for hemolysis. 
 DISCHARGE CRITERIA: 
1) Stabilized platelet count > 10,000cells/cu mm 
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2) No age related or social risk factor for head injury. Patients should be 
counseled regarding contact sports and high risk activities like 
jumping and diving from height 
3) No active bleeding. 
INDICATIONS TO TREAT PERSISTENT/CHRONIC ITP: 
1. Clinical bleeding 
2. Any surgery where there is a need to improve the platelet 
counts temporarily. 
3. Extremely low platelets which increases the risk of bleeding  
4. Patients who participate in sports or other high risk endevours. 
NEWLY DIAGNOSED ITP- FIRST LINE THERAPY:
5 
Corticosteroids: 
Dexamethasone, methylprednisolone or prednisolone can be used for 4-6 
weeks. Initial response is seen in 90 to 95% of patients. Sustained response 
is seen in 5o to 80% of patients. Toxicity depends on the length of 
administration. Side effects include fluid retention, Cushingoid facies, 
insomnia, mood swings, anxiety, weight gain, anger, diabetes, GI distress, 
25 
 
ulcers, hypertension, skin changes, alopecia, osteoporosis, 
immunosuppression, opportunistic infection, adrenal insufficiency. Repeated 
dosing decreases the tolerability. Short term bolus therapy also lowers the 
risk of adverse events. 
IV Anti-D Immunoglobulin: 
Anti-Rh (D) 50-70μg/kg. Initial response rate is 80% and sustained response 
lasts for 2 to 4 weeks but in some patients it may persist for months. Adverse 
effects include fever, chills, intra-vascular hemolysis, DIC and renal failure. 
It should be used only in Rh positive individuals as it acts by producing 
limited hemolysis. Post infusion the patient should be monitored for 8 hours 
to observe for severe intravascular hemolysis which occurs rarely. 
IV Immunoglobulin: 
0.4g/kg/day for 5 days. Rapid response occurs initially in 80% of the 
patients but is sustained only for 2 to 4 weeks. Side effects include nausea, 
diarrhea, flushing, fatigue, fever, chills, transient neutropenia, thrombosis, 
tachycardia, blood pressure changes, tachycardia, aseptic meningitis and 
renal insufficiency. Anaphylactoid reactions can occur in patients with IgA 
deficiency. In such patients IgA deficient immunoglobulin can be used. 
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SECOND LINE APPROACHES: 
If the response after initial treatment for one month is not very satisfying and 
once the patient starts to develop steroid related toxicities second line 
therapy can be tried. Either monotherapy with danazol or a combination of 
dapsoneand azathioprine can be tried as steroid sparing agents. 
Splenectomy: 
The standard line of treatment for ITP patients who do not respond well to 
prednisolone is Splenectomy. Some have a partial response while two thirds 
have a long term durable response. Laparoscopic Splenectomy done by 
experienced surgeons have less mortality and morbidity. Complications 
include hemorrhage, overwhelming sepsis syndrome, wound infection , 
thrombosis, sub phrenic abscess, pneumococcal infection, peri-pancreatic 
necrosis and death .Complications can be reduced by following the 
recommended vaccination protocols (especially for Hemophilus influenza, 
pneumococcus and menningococcus) and proper initiation of antibiotics 
when the first symptoms of a systemic febrile illness appear. Although it is 
recommended only by few physicians it is cost effective and has the highest 
chance for long term remission. Long term complications include defective 
immunity, atherosclerosis and pulmonary hypertension. 
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Anti-CD20 Antibody: Rituximab 375 mg/m
2
 weekly for 4 weeks. Fever, 
chills and throat scratchiness can occur. Sustained response occurs only in 
20 to 30% patients. Severe reactions include anaphylaxis, serum sickness, 
infection, bronchospasm, pulmonary embolism, infection and retinal artery 
thrombosis. It may cause fulminant hepatitis in patients with hepatitis b 
infection and hence is contraindicated in such patients. Rare cases of 
progressive multifocal leucoencephalopathy has also been reported in 
patients who are HIV negative with the use of Rituximab. 
TRAs (Thrombopoetin receptor agonists):Romiplostin, eltrombopag are the 
two FDA approved TRAs used in primary ITP in patients who need 
continuous treatment after the initial course of corticosteroids. 
Romiplostin is a peptide given subcutaneously which prolongs the half-life 
of the thrombopoietin receptor. Many patients who were given this drug had 
a better quality of life as they could discontinue corticosteroids. 
Eltrombopag is an oral drug which reduced the need for rescue therapy. 
Both these drugs might lead to increased reticulin deposition in the bone 
marrow and may ultimately lead to bone marrow fibrosis. Certain trials have 
demonstrated a rebound thrombocytopenia in about 10% of the patients with 
the discontinuation of these drugs. Some studies have demonstrated 
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increased risk of venous thrombosis especially in hepatitis c virus positive 
individuals who take eltrombopag. Periodic ophthalmologic examinations 
and liver function tests should also be done in patients taking eltrombag as 
they are known to cause hepatobiliary abnormalities and cataract. These 
agents are mainly used for refractory cases of ITP. 
THIRD LINE THERAPY: 
Immunosuppressive drugs like azathioprine, mycophenolate mofetil, 
cyclosporine and cyclophosphamide; used either alone or in combination has 
been tried in patients not responding to either the first line or second line 
therapies. They have very little efficacy. Hematopoietic stem cell 
transplantation and drugs like vinca alkaloids are tried only for resistant 
cases. These drugs have a very limited safety profile and hence only tried as 
a last resort for unresponsive patients. 
CRITERIA TO ASSESS TREATMENT RESPONSE IN ADULT ITP: 
Complete response: When after treatment the platelet count is at least 
1,00,000 cells/cu mm. and there should be no bleeding. 
Response:  When the baseline platelet count doubles and the platelet counts 
should be in the range between 30,000 to 1,00,000cells/ cu mm. ,in the 
absence of bleeding. 
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Time to response is defined as the time when the treatment is started to the 
time when the patient achieves either complete response or response. The 
time to assess response depends on the type of treatment. 
INITIAL AND PEAK RESPONSE FOR DIFFERENT AGENTS:
3 
AGENT INITIAL 
RESPONSE(Days) 
PEAK 
RESPONSE(Days) 
Prednisolone 4-14 7-28 
Dexamethasone 2-14 4-28 
IV Ig 1-3 2-7 
Anti-D 1-3 3-7 
Rituximab 7-56 14-180 
Splenectomy 1-56 7-56 
Danazol 14-90 28-128 
Azathioprine 30-90 30-180 
Vincristine 7-14 7-42 
Eltrombopag 7-28 14-90 
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No response: there is no doubling of the baseline platelet count and the 
platelet count continues to be <30,000 cells/cu mm or the patient continues 
to bleed. 
Duration of response: It is measured as the time interval between the 
achievement of complete response or response to the loss of complete 
response or response. It is measured as the proportion of cumulative time the 
patients spends in complete response or response during the period under 
examination. 
Corticosteroid dependence: when there is ongoing need for continuous 
administration of steroids or the patient needs frequent course of steroids to 
avoid bleeding or to maintain platelets ≥30,000cells/ cu mm. Patients who 
are dependent on steroids or other treatment modalities are considered as 
non-responders. 
REFRACTORY ITP: 
The patients are labeled as refractory cases if they meet all  the following 
criteria 
1) Patients who fail to achieve response after splenectomy or if they relapse. 
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2) Patients who have severe ITP or risk of major bleeding which requires 
treatment. Need of adjunctive or on demand therapy will not qualify the 
patient as refractory. On demand therapy is defined as one in which the 
platelet count is temporarily increased in case of a major bleed or trauma or 
sufficiently safety levels to perform any invasive procedures. Any non-ITP 
specific therapy used to decrease bleeding like platelet transfusion, hormonal 
agents, anti-fibrinolytic drugs desmopressin, fibrin sealants etc are 
considered as adjunctive treatment. 
3) Primary ITP confirmed after exclusion of other secondary causes of 
thrombocytopenia. 
Response to therapy in refractory ITP is defined as ability to maintain 
platelet count to prevent significant bleeding. They represent only < 10% of 
adult ITP. 
HELICOBACTER PYLORI AND ITP
5
: 
As the detection and the eradication of H.pylori is inexpensive, safe and well 
tolerated it has been proposed as a routine test in the initial evaluation of 
patients with ITP. This is considered appropriate in areas where the H.pylori 
infection prevalence is high. Further investigations and studies are required 
to prove the relationship between ITP and H.pylori. 
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HELICOBACTER PYLORI: INTODUCTION: 
Warren and Marshell from Australia observed spiral, campylobacter like 
bacteria in close apposition to the gastric mucosa in several cases of gastritis 
and peptic ulcer. They named it Campylobacter pylori. Since they had 
several characters which were different from Campylobacter they were 
renamed later as Helicobacter pylori. 
HELICOBACTER PYLORI: MORPHOLOGY 
 
It is a gram negative spiral rod which is motile by a unipolar tuft of 
lophotrichous flagella. It grows on chocolate agar under microaerophilic 
conditions with pH 6 to 7 and CO2 5-20%.It produces oxidase, catalase, 
phosphatase and H2S. H.pylori resides in the gastric mucus and it has several 
acid resistant mechanisms to protect itself. It has the unique property of 
producing urease, which hydrolyses urea to form ammonia which acts as a 
buffer in the acidic medium of the stomach. 
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There are several non-pylori gastric helicobacters which are acquired as 
zoonosis. There are also non gastric Helicobacter (intestinal) which includes 
H.cinnaedi and H.fennelliae and cause proctitis in HIV patients. 
Colonization with H.pylori is a risk factor for peptic ulcer disease (both 
gastric and duodenal ulcers), gastric MALT lymphoma and gastric 
adenocarcinoma. Recent studies have shown that H.pylori colonization is a 
risk factor for iron deficiency anemia, rheumatoid arthritis, ITP etc. It is 
shown to be protective against asthma, obesity and GERD.  
EPIDEMIOLOGY: The prevalence in developing countries is >80% and in 
developed countries it is around 30%. The prevalence increases with age. 
Infection is usually acquired in childhood. Risk factors for colonization of 
H.pylori include over-crowding and maternal colonization the low incidence 
in children of developed countries is due to increased use of antibiotics and 
decreased rates of maternal colonization. The only important reservoir of 
H.pylori is humans. Infection is usually acquired by the feco-oral route 
PATHOLOGY AND PATHOGENESIS: 
H.pylori causes a chronic superficial gastritis in which there is infiltration of 
the gastric mucosa by polymorphonuclear and mononuclear cells. There is a 
chronic persistent immune response due to H.pylori colonization. It activates 
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both humoral and cell mediated immune responses. Both and systemic 
antibodies are produced. However the bacterium is not cleared, this is 
because H.pylori down regulates the immune system. 
Every person colonized by H.pylori is not symptomatic only a few develop 
overt disease. This is due to certain host factors, environmental factors and 
bacterial strain differences .Certain virulence factors include CagA, VacA, 
adhesins such as BabA, SabA and DupA. CagA induces inflammatory, 
cytoskeletal and proliferative changes. It also affects the host cell signal 
transduction. This leads to gastric inflammation and peptic ulcer disease and 
gastric adenocarcinoma. 
Host factors include genetic polymorphisms of cytokine genes and genes 
that encode for toll like receptor. Environmental factors include smoking, 
high salt diet and preserved food. Diet rich in anti-oxidants and vitamin C 
are protective. 
Pan gastritis and corpus predominant gastritis leads to gastric ulceration and 
adenocarcinoma whereas antral predominant gastritis leads to duodenal 
ulcer. Somatostatin reduces gastrin levels. H.pylori inflammation leads to 
depletion of somatostatin producing D cells hence during meals more 
secretions are produced which leads to antral inflammation. The 
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pathogenesis of gastric adenocarcinoma is not clear as hypochlorhydria 
occurs despite hypergastrinemia. The following sequence occurs in intestinal 
type of adenocarcinoma, initially there is simple gastritis then gastric 
atrophy leading to intestinal metaplasia and dysplasia. Chronic gastritis leads 
to diffuse type of adenocarcinoma. 
Pathogenesis in H.pylori and ITP: 
Molecular mimicry is the most popular hypothesis to explain the mechanism 
by which ITP is triggered by H.pylori infection. It induces antibody 
production against certain antigens which cross react with the platelet 
antigens
7
.The antigen most commonly implicated is CagA and once H.pylori 
is eradicated, antibodies against CagA disappear from serum .This is 
supported by studies from Italy where Cag A gene positivity was more 
prevalent in ITP patients than the control group. Another hypothesis is the 
induction of Th1 phenotype which favors the onset and persistence of ITP
8
. 
CagA positive strains may be more prevalent in developing word and less 
prevalent in the developed countries. These genotypic variations in 
distribution might explain why response is seen only in certain geographic 
areas .Some studies have shown that presence of H.pylori antibodies causes 
platelet aggregation by binding to Von Willibrand’s factor and inducing 
glycoprotein 1b
8
. There are several alternative theories and none are 
36 
 
mutually exclusive. Confirmatory studies are still needed to confirm these 
hypotheses. 
Genome: 
H.pylori consists of a large diversity of strains, and the genomes of three 
have been completely sequenced. The genome of the strain "26695" consists 
of about 1.7 million, base pairs with some 1,550 genes. The two sequenced 
strains show large genetic differences, with up to 6% of the nucleotides 
differing.  
Study of the H. pylori genome is mainly centered on attempts to understand 
pathogenesis that is, the ability of this organism to cause disease. 
Approximately 29% of the loci are in the "Pathogenicity Island". Two of 
sequenced strains have a very long Cag pathogenicity island (a common 
gene sequence believed responsible for pathogenesis) that contains over 40 
genes. This pathogenicity island is usually absent from H. pylori strains 
isolated from humans who are carriers of H. pylori, but remain 
asymptomatic. 
The CagA gene codes for one of the major H. pylori virulence proteins. 
Bacterial strains that have the CagA gene are associated with an ability to 
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cause ulcers. The CagA gene codes for a relatively long  protein. The cag 
pathogenicity island has about 30 genes, which code for a complex secretion 
system. 
Types of Anti-bodies: 
 
 
38 
 
Generation of three types of antibodies has been proposed: 
1) H.pylori antibodies bind to Von Willibrand's factor and platelet 
glycoprotein. So platelets get activated and are cleared. 
2) Somatic mutation of the organism leads to formation of second generation 
antibodies. They either detects the bacterial protein bound to the platelet or 
cross react with the platelet antigens. At this stage the patient responds to 
therapy with antibiotics. 
3) Patients who are not responsive to therapy develop further somatic 
mutation which leads to formation of third generation of antibodies. These 
antibodies lose their activity against the organism but retain their activity 
against the platelets. 
CLINICAL FEATURES: 
H.pylori is the main cause of peptic ulcer disease both gastric and duodenal 
ulcer. It also is responsible for non-cardia adenocarcinoma of stomach and 
primary gastric lymphoma. Functional or non-ulcer dyspepsia is one in 
which patient has symptoms pertaining to the upper gastrointestinal system 
but upper gastrointestinal endoscopy shows normal results. The association 
of H.pylori with dyspepsia is not clear. H.pylori seems to have a protective 
role in GERD, Barrett’s esophagus and adenocarcinoma of gastric cardia and 
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esophagus. Pernicious anemia and autoimmune gastritis are also precipitated 
by H.pylori. It also leads to iron deficiency anemia by causing occult blood 
loss, reducing iron absorption and causing hypochlorhydria. 
H.pylori has also been implicated in certain extra-gastrointestinal 
pathologies. But the evidence of causality is less strong, included under this 
are ITP, coronary artery disease and cerebrovascular disease. Recent studies 
have shown a protective role of CagA
+ 
 H.pylori in childhood asthma, atopic 
disorders and hay fever
1
. 
DIAGNOSIS: 
Two groups of tests are available, invasive tests in which endoscopy tests are 
done and biopsy samples are analyzed and noninvasive tests. Endoscopy is 
usually done for older patients in whom adenocarcinoma is suspected, it is 
never the initial procedure of choice for young patients with dyspepsia. Once 
endoscopy is performed two biopsy specimens are taken from the antrum. 
They can be subjected to histological examination which is more accurate in 
identifying H.pylori. Specials stains like silver stain or modified Geimsa 
stains are available which helps in optimal visualization of the organism. It 
also provides additional information like the degree and pattern of 
inflammation, atrophy, metaplasia and dysplasia. The biopsy urease test is 
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the most convenient biopsy based test. The biopsy specimens are placed in a 
gel containing urea and an indicator. pH alteration occurs if H.pylori urease 
is present and this leads to color change, and it usually occurs in minutes but 
may take as long as 24 hours. Cultures can be done and H.pylori confirmed 
by its typical appearance on gram stain and positive biochemical tests like 
oxidase, catalase and urease. Culture has the advantage that the organisms’ 
antibiotic sensitivity can be determined and can be useful clinically. 
Non-invasive tests include the urea breath test which is accurate. The 
patients drinks a solution containing urea labeled nonradioactive 
13
C and 
later blows into a tube .If H.pylori urease is present then it will hydrolyze 
urea and labeled carbon dioxide will be detected in blood samples. The stool 
antigen test is less expensive, more convenient and simple assay but is 
slightly less accurate when compared to the urea breath test. Serological 
assays using immunoblot or enzyme linked immunosorbent assay to detect 
H.pylori specific IgG antibodies are also available. 
Success to treatment can be assessed using the biopsy based tests, stool 
antigen tests and the urea breath tests. Serological tests cannot be used to 
monitor treatment because it takes time for the H.pylori specific antibodies 
to drop and it not practical to monitor this gradual fall in H.pylori antibodies. 
All these tests are dependent on the H.pylori load and hence the patient 
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should be off any antibiotics when they are done or it may be false negative. 
Similarly follow up endoscopy is a must in patients with gastric ulcer to see 
if the ulcer has healed and to monitor for gastric carcinoma. 
COMMONLY USED TESTS TO DETECT H.PYLORI: 
TEST ADVANTAGES DISADVANTAGES 
INVASIVE (based 
on endoscopic 
biopsy) 
  
Rapid urease test Simple and quick Some tests are not 
fully sensitive before 
24 hours 
Histology Gives additional 
information 
Sensitivity depends 
on use of special 
stains and experience 
Culture Antibiotic 
susceptibility 
determined 
Sensitivity depends 
on experience 
NONINVASIVE   
Serology Convenient, cost Not used for follow 
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effective. Not 
effected by PPIs or 
antibiotics 
up and is less 
accurate. 
13
C urea breath test Simple, 
inexpensive, used 
for follow up 
Not very convenient, 
requires fasting. 
Stool antigen test Convenient, cost 
effective, used for 
follow up. 
Disliked by people, 
less accurate 
 
 
Indications to treat H.pylori include gastric or duodenal ulcer or any low 
grade B cell lymphoma. Monotherapy is usually not indicated because of 
inadequate delivery of antibiotic to the colonization niche. Hence triple and 
quadruple regimens are used which have eradication rates > 90% Recently 
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PPIs and ranitidine bismuth citrate and two or three antibiotics are used for7 
to 14 days. Successful H.pylori treatment depends upon two main factors the 
compliance of the patients and the use of antibiotics to which the infecting 
strains are susceptible.  
TREATMENT REGIMENS RECOMMENDED FOR H.PYLORI: 
REGIMEN DRUG 1 DRUG 2 DRUG 3 DRUG 4 
OCA 
7 to 14 days 
Omeprazole 
20mg bid 
Clarithromycin 
500mg bid 
Amoxicillin 
1g bid 
 
OCM 
7 to 14 days 
Omeprazole 
20mg bid 
Clarithromycin 
500mg bid 
Metronidazole 
500mg bid 
 
OBTM 
14 days 
Omeprazole 
20mg bid 
Bismuth 
subsalicylate 
2tablets qid 
Tetracycline 
HCl 500mg qid 
Metronid
azole 
500mg 
tid 
sequential (5 d + 
5 d) 
Omeprazole 
20mg bid 
Amoxicillin 1g 
bid 
  
Omeprazole 
20 mg bid 
Clarithromycin 
500mg bid 
Tinidazole 500 
mg bid 
 
5.- OAL 
10 days 
Omeprazole 
20mg bid 
Amoxicillin 1 g 
bid 
Levofloxacin 
500mg qid 
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PREVENTION : 
 Proper sanitation 
 Good personal hygiene. 
 Hygienic food habits 
 Vaccination 
 Prevent overcrowding 
INFECTION INDUCED THROMBOCYTOPENIA: 
The most important cause for non iatrogenic thrombocytopenia is due to 
viral and bacterial infections. Most Gram negative sepsis are associated with 
DIC Infections can affect both platelet production and platelet survival. 
There is also immune mediated platelet destruction. In children ITP is 
usually due to viral infection. A bone marrow examination is usually done in 
occult infections. 
DRUG INDUCED THROMBOCYTOPENIA: 
Use of many drugs has been associated with thrombocytopenia. many 
chemotherapeutic agents, over the counter drugs and herbal drugs have been 
implicated. Classic drug induced antibodies against the platelets have been 
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detected mainly against chloroquine and sulphonamides. The 
thrombocytopenia typically occurs within 21 days of drug exposure and the 
patient recovers within 10 days of stopping the drug. Abciximab differs from 
other drugs in that the thrombocytopenia typically occurs within 24 hours of 
exposure. The drugs are given below: 
Acetaminophen, Aminosalicyclic acid ,Amiadarone ,Ampicilin 
,Carbamezepine ,Danazol ,Diclofenac ,Digoxin ,Ethambutol ,Frsemide 
,Imipenem/cilastatin ,Ibuprofen ,Linezolid ,Methydopa, Phenytoin, 
Rifampin,Valproic acid, Vancomycin, Sulpha group of drugs. 
HEPARIN INDUCED THROMBOCYTOPENIA: 
It differs from other drug induced thrombocytopenia in two ways: 
1) It does not cause severe thrombocytopenia that is platelet counts < 20,000 
2) It does not cause bleeding but is instead associated with increased risk of 
thrombosis 
Here antibodies are formed against platelet factor 4 and the platelet gets 
activated and is removed by the reticuloendothelial system it occurs after 
exposure to both unfractionated heparin and low molecular weight heparin 
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Platelets drop 5 to 15 days after exposure. The four T's associated with HIT 
include: 
Timing of exposure 
Thrombosis 
Thrombocytopenia and 
Other causes of low platelet not evident. 
The antibodies produced can be detected by ELISA. 
Heparin should be stopped and other drugs like argatroban and lipuridin 
which are direct thrombin inhibitors should be used. 
INHERITED THROMBOCYTOPENIA: 
It can be autosomal dominant, autosomal recessive or X- linked pattern. 
AD ; Common feature is large platelets.It includes May Hegglin anomaly 
and Sebastin, Epsteins and Fechtner syndrome. 
AR includes Bernard Soulier syndrome, Thrombocytopenia with absent 
radii. Congenital amegakaryocytic thrombocytopenia. 
X linked include Wiskott Aldrich syndrome and dyshematopeotic syndrome 
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   MATERIALS AND METHODS 
SETTING 
                  This study is conducted in the Medicine department of Madras 
medical college in collaboration with Department of Hematology and 
Department of Gastroenterology along with the support of the Pathology, 
Biochemistry and Microbiology departments. 
ETHICAL APPROVAL 
Obtained. 
STUDY DURATION 
                    This study was conducted over a period of 6 months. 
STUDY POPULATION 
                     Patients admitted with acute onset ITP in the medical wards 
and ITP patients who are on regular follow up in the Hematology 
department of Rajiv Gandhi Government General Hospital. 
TYPE OF STUDY 
                      Cross sectional study. 
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INCLUSION CRITERIA 
                     Patients with ITP in whom the secondary causes of ITP have 
been ruled out 
EXCLUSION CRITERIA 
APLA 
HIV patients 
Hepatitis C virus positive patients 
SLE 
Lymphoproliferative disorders 
Drug induced thrombocytopenia 
Children < 10 years 
Pregnant women 
Chronic renal disease 
Chronic liver disease patients 
Pseudothrombocytopenia 
SLE 
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SAMPLE SIZE 
50 patients with ITP who are stable with no active bleeding and stable 
platelet counts. 
METHODS 
                Patients with ITP on regular follow up in the Hematology 
Department of the Rajiv Gandhi Government General Hospital will be asked 
questions as per a questionnaire and will be subject to clinical examination. 
All the secondary causes of ITP will be ruled out using appropriate tests.  
Patients will be grouped as per age, sex and platelet counts. Patients who 
have dyspeptic symptoms will be identified. Routine lab investigations will 
be done. Platelets counts will be done before endoscopy. Patients with stable 
platelet counts and no active bleeding will then be subject to Upper GI 
endoscopy in the Medical Gastroenterology Department and the findings 
will be recorded. A biopsy will be taken from the antrum and the biopsy will 
be subject to Rapid urease test to detect H.pylori. Patients who turn out to be 
positive will be put on H.pylori regimen 
STATISTICAL ANALYSIS: 
Results were analyzed using chi square test and Fischer’s exact t test. 
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OBSERVATION AND RESULTS 
SEX AND ITP: 
SEX FREQUENCY PERCENTAGE 
MALE 11 22 
FEMALE 39 78 
 
 
 
Male to female ratio: 1:3.5. 
 
 
MALE 
22% 
 
 
FEMALE 
78% 
 
SEX 
MALE 
FEMALE 
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SEX AND H.PYLORI POSITIVITY: 
SEX FREQUENCY HP POSITIVE HP NEGATIVE 
MALE 11 4(36%) 7(64%) 
FEMALE 39 14(35.89%) 25(64.1%) 
 
 
P value is 1(not significant) 
 
 
 
 
male female 
36 36 
64 64 
h.pylori pos h.pylori neg 
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AGE AND ITP: 
AGE FREQUENCY PERCENTAGE MALE FEMALE 
11-20 10 20 1 9 
21-30 16 32 3 13 
31-40 13 26 4 9 
41-50 7 14 3 4 
51-60 4 8 - 4 
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H.PYLORI POSITIVITY WITH RELATION TO AGE: 
AGE FREQUENCY HP POSITIVE HP NEGATIVE 
11-20 10 2 8 
21-30 16 8 8 
31-40 13 4 9 
41-50 7 3 4 
51-60 4 1 3 
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RESIDENCE AND ITP: 
RESIDENCE FREQUENCY PERCENTAGE 
URBAN 38 76% 
RURAL 12 24% 
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H.PYLORI POSITIVITY WITH RELATION TO RESIDENCE: 
RESIDENCE FREQUENCY HP POSITIVE HP NEGATIVE 
URBAN 38 13(34%) 24(66%) 
RURAL 12 5(41%) 8(59%) 
 
 
P value is 0.7(not significant) 
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SOCIOECONOMIC STATUS AND ITP: 
SES FREQUENCY PERCENTAGE 
LOWER CLASS 42 84 
UPPER CLASS 8 16 
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H.PYLORI POSITIVITY AND SOCIOECONOMIC STATUS: 
SES FREQUENCY HP POSITIVE HP NEGATIVE 
LOWER CLASS 42 15(36%) 27(64%) 
UPPER CLASS 8 3(37%) 5(63%) 
 
 
P value is 1(not significant) 
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BLEEDING AND ITP: 
BLEEDING FREQUENCY PERCENTAGE 
YES 44 88 
NO 6 12 
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MEAN AGE AND MEAN PLATELET COUNT IN ITP PATIENT WITH 
AND WITHOUT BLEEDING: 
BLEEDING MEAN AGE (YEARS) MEAN PLATELET 
COUNT 
YES 32.54 26613 
NO 27 37000 
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60 
 
H.PYLORI POSITIVITY IN BLEEDING ITP PATIENTS: 
BLEEDING FREQUENCY HP POSITIVE HP NEGATIVE 
YES 44 17(38%) 27(62%) 
NO 6 1(16%) 5(84%) 
 
 
P value is 0.3(not significant). 
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MEAN PLATELET COUNT IN PATIENTS WITH BLEEDING AND 
H.PYLORI POSITIVITY: 
BLEEDING HP POSITIVE MEAN PLATELET 
COUNT 
YES 17 17823 
NO 1 32000 
 
 
 
 
 
HP POSITIVE 
HP NEGATIVE 
17823 
32148 
MEAN PLATELET COUNT 
MEAN PLATELET COUNT 
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MEAN PLATELET IN ASYMPTOMATIC H.PYLORI POSITIVE 
PATIENTS: 
 NO BLEEDING MEAN PLATELET 
HP POSITIVE 1 32000 
HP NEGATIVE 5 38000 
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SKIN RASH AND ITP: 
SKIN RASH FREQUENCY PERCENTAGE 
YES 32 64 
NO 18 36 
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H.PYLORI POSITIVITY AND SKIN RASH IN ITP: 
SKIN RASH HP POSITIVE HP negative 
YES 15(47%) 27(53%) 
NO 3(17%) 15(83%) 
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H.PYLORI POSITIVITY IN ITP PATIENTS WITH 
SKIN RASH  
HP POSITIVE HP NEGATIVE 
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DYSPEPSIA AND ITP: 
DYSPEPSIA FREQUENCY PERCENTAGE 
YES 13 26 
NO 37 74 
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DYSPEPSIA AND H.PYLORI POSITIVITY IN ITP: 
DYSPEPSIA FREQUENCY HP POSITIVE HP NEGATIVE 
YES 13 1(7%) 12(93%) 
NO 37 17(46%) 20(54%) 
 
P value is 0.3 (not significant) 
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PLATELET COUNT AND ITP: 
 
PLATELET 
COUNT 
FREQUENCY PERCENTAGE 
<30000 30 60% 
31000 TO 60000 17 34% 
61000 TO 100000 3 6% 
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H.PYLORI POSITIVITY AND PLATELET COUNT: 
 
PLATELET 
COUNT 
HP POSITIVE HP NEGATIVE 
<30000 14(46%) 16(54%) 
31000 TO 60000 4(24%) 13(76%) 
60000 TO 100000 - 3(100%) 
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100 
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MEAN PLATELET COUNT IN H.PYLORI POSITIVE PATIENTS: 
ITP MEAN PLATELET COUNT 
HP POSITIVE 10971.29 
HP NEGATIVE 17709.80 
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ENDOSCOPY AND ITP: 
GASTRITIS FREQUENCY PERCENTAGE MEAN 
PLATELET 
PRESENT 21 42 26571.42 
ABSENT 29 58 28793.10 
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ENDOSCOPY (GASTRITIS) AND H.PYLORI POSITIVITY: 
GASTRITIS FREQUENCY HP 
POSITIVE 
HP 
NEGATIVE 
YES 21 10(47%) 11(53%) 
NO 29 8(27%) 21(73%) 
 
P value is 0.23(not significant) 
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DURATION OF SYMPTOMS AND ITP: 
DURATION FREQUENCY PERCENTAGE MEAN 
PLATEL
ET 
<3 MONTHS 3 6 20000 
3-12 MONTHS 11 22 29545 
>12 MONTHS 33 66 28606 
REFRACTORY 3 6 21333 
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DURATION OF SYMPTOMS AND H.PYLORI POSITIVITY: 
DURATION FREQUENCY POSITIVE NEGATIVE 
< 3 MONTHS 3 2 (66.66%) 1 (33.33) 
3 – 12 
MONTHS 
11 4 (36.36%)  7 (63.63) 
> 12 MONTHS 33 11 (33.33%) 22 (66.66%) 
REFRACTORY 3 1 (33.33%) 2 (66.66%) 
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MEAN PLATELET BASED ON DURATION AND HP POSITIVITY: 
DURATION HP POSITIVE MEAN 
PLATELET  
< 3MONTHS 2 12500 
3 TO 12 MONTHS 4 11250 
>12 MONTHS 11 23181 
REFRACTORY 1 10000 
 
MEAN PLATELET BASED ON DURATION AND HP NEGATIVITY: 
DURATION HP NEGATIVE MEAN 
PLATELET 
< 3 MONTHS 1 35000 
3 TO 12 MONTHS  7 40000 
>12 MONTHS 22 31318 
REFRACTORY 2 27000 
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H.PYLORI POSITIVITY IN ITP: 
ITP FREQUENCY PERCENTAGE 
HP POSITIVE 18 36 
HP NEGATIVE 32 64 
 
 
 
 
 
 
36% 
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RESULTS: 
Our study was a cross sectional study in which we evaluated 50 patients with 
ITP. We analyzed their clinical profile and did an antral biopsy and 
subjected the specimen to rapid urease test, to detect the H.pylori status of 
the ITP patients. 
SEX: 
Out of the 50 patients 39 were female and 11 were male. The female: male 
ratio was 3.5:1. The frequency of H.pylori infection was equal among 
females (35.89%) and males (36%) although ITP was more common among 
females. 
AGE: 
Among the 50 patients 16 were in the third decade and 13 in the fourth 
decade and H.pylori positivity was also common in this age groups. 
Mean age of ITP was 31.9 years (±12.42). 
Mean age in males was 33.27 years and mean age in females was 31.5 years. 
Mean age of H.pylori positive ITP patients was 32.4(±12.09) years and 
mean age of H.pylori negative ITP patients was 31.53(±29.0) years. 
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Mean age of H.pylori positive males (40±4.7 years) was higher than 
H.pylori positive females (30.28±12.79 years). 
RESIDENCE: 
In our study 38(76%) were from urban area and 12(24%) from rural area. 
H.pylori positivity was more in rural population 41% (5 positive among 12) 
and it was 34% in urban area 34% (13 positive among 38). 
Mean platelet in H.pylori positive individuals from urban and rural 
population was the same, It was 17,472.5 cells/cu.mm. 
SOCIOECONOMIC STATUS: 
Applying the Kuppusamy's criteria it was found that 84% (42 of 50) were 
from the lower class and 16% (8 of 50) from upper class. The frequency of 
H.pylori positivity was equal in both the upper class (37.5%) and lower class 
(35.7%). 
CLINICAL PROFILE: 
Bleeding: 88% (44 of 50) presented with bleeding and 12% (6 of 50) were 
asymptomatic. Among the patients with bleeding 50% had major bleed (GI 
bleed, genitor-urinary and intra cranial) and 50% presented with minor 
bleed(skin and mucous bleed). 
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H.pylori positivity was more frequent in patients with bleeding 38% (17 of 
44 positive) than patients without bleeding 16% (1 of 6). 
Mean platelet in ITP patients with bleeding and H.pylori positive was 17823 
cells/cumm and H.pylori negative patients was 32148 cells/cumm. 
Mean platelet in asymptomatic ITP patients and H.pylori positive was 32000 
and H.pylori negative was 3800 cells /cumm. 
Skin rash: 64% (32 of 50) of ITP patients had skin rash and H.pylori 
positivity was seen in 47% (15 positive of 32) of these patients. H.pylori 
positivity among patients without skin rash was only 16.6%. 
Dyspepsia: Out of 50 patients only 13(26%) had dyspepsia and 74% had no 
dyspepsia. H.pylori positivity was only 7% among patients with dyspepsia 
as compared to 46% positivity in patients without dyspepsia. 
PLATELET COUNT: 
In our study 60% (30 of 50) had platelet counts less than 30000 and 34% (17 
of 50) had platelet counts between 31000 and 60000 and6%(3 of 50) had 
platelet counts between 60000 and 100000. The mean platelet count of ITP 
patients was 27860(±17007.81) cells/cu mm. 
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All the 18 H.pylori positive patients had platelet counts less than 60,000, out 
of these 77%(14 of 18) had platelet <30000 and 23% (4 of 18) had platelet 
counts between 31000 and 60000. The mean platelet of H.pylori ITP patients 
was 10971(±10971.29)cells/cu mm and mean platelet of H.pylori negative 
ITP patients was 33062.5(±17709) cells/cu mm. 
ENDOSCOPY (GASTRITIS): 
Out of 50 patients 21 (42%) had gastritis on endoscopy and of these 47% (10 
of 21) were positive for H.pylori. The remaining 29 (58%) did not have 
gastritis on endoscopy and of these only 27% (8 of 29 ) were H.pylori 
positive. 
Out of 18 ITP patients positive for H.pylori 55% (10 patients) had gastritis 
on endoscopy. 
The mean platelet count of H.pylori positive ITP patients with gastritis was 
18100 and H.pylori negative ITP patients with gastritis was 34272 cells/cu 
mm. 
The mean platelet of H.pylori positive patients without gastritis was 19250 
and H.pylori negative patients without gastritis was 32,428 cells/cumm. 
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BLOOD GROUP:  
In our study majority of the patients had O positive (54%) and B positive 
blood groups (22%). 
14% were A positive, 4% AB positive , 4% B negative and 2% O negative 
respectively. 
14 out of the 18 H.pylori positive patients were O positive. (77%). 
DURATION OF ITP: 
In our study 66% (33 of 50) had chronic ITP, 22% (11 of 50) had persistent 
ITP, 6% (3 of 50) had ITP of less than 3 months duration and 6% (3 of 50) 
had refractory ITP that is had spleenectomy done. The mean duration of ITP 
patients included in our study was 29.44(±25.331) months 
61% (11 of 18) H.pylori positive ITP patients had chronic ITP,22% (4 of 18) 
had persistent.ITP 11% (2 of 18) had acute ITP and 6% (1 of 18) had 
refractory ITP. 
H.pylori frequency was more among patients with acute ITP (66.66%) when 
compared to patients with persistent ITP (36.66%), chronic ITP (33.33%) 
and refractory ITP (33.33%). 
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The mean platelet of patients with H.pylori positive ITP was low (14232 
cells/cumm) in all four groups compared to H.pylori negative ITP patients 
(333329 cells/cumm). 
PREVALENCE OF H.PYLORI IN ITP: 
Out of the 50 ITP patients 18 were H.pylori positive that is the prevalence 
was 36%. 32(64%) were H.pylori negative. 
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DISCUSSION: 
CLINICAL CHARECTERISTICS OF H.PYLORI POSITIVE AND 
H.PYLORI NEGATIVE ITP PATIENTS: 
CLINICAL 
FEATURES 
H.PYLOR
I 
POSITIVE 
H.PYLORI 
NEGATIV
E 
P 
VALU
E 
SIGNIFICANC
E 
SEX(M/F) 4/14 7/25 1 NS 
RESIDENCE(U/R
) 
13/5 24/8 0.7 NS 
SES(UC/LC) 3/15 5/27 1 NS 
BLEEDING(Y/N) 17/1 27/5 0.3 NS 
SKIN RASH(Y/N) 15/3 17/15 0.06 NS 
DYSPEPSIA(Y/N) 1/17 12/20 0.32 NS 
ENDOSCOPY 
(Y/) 
(GASTRITIS) 
10/8 11/21 0.23 NS 
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P value <0.05 is considered statistically significant.          
NS : Not significant 
U/R : Urban/Rural,        Y/N : Yes/No,          M/F : Male/Female 
SES : Socioeconomic Status,         UC/LC : Upper class/Lower class. 
Group Statistics for age, duration and platelet count: 
 RUT N Mean 
Std. 
Deviation 
Std. 
Error 
Mean 
Platelet 
count 
Positive 
18 
18611.
11 
10971.293 
2585.9
59 
Negative 
32 
33062.
50 
17709.005 
3130.5
39 
Duration Positive 18 31.00 29.927 7.054 
Negative 32 28.56 22.823 4.035 
AGE Positive 18 32.44 12.099 2.852 
Negative 32 31.59 12.791 2.261 
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P values 
Parameters P value Interpretation 
Mean age 0.8 NS 
Mean duration 0.76 NS 
Mean platelet count 0.003 S 
NS- not significant  S-significant 
CLINICAL CHARACTERISTICS: 
AGE: Several studies have shown that ITP patients infected with H.pylori 
were found to be significantly older than ITP patients not infected with 
H.pylori.
8, 14
 Prevalence of H.pylori increases with increasing age mostly 
seen in patients more than 30years.In our study mean age in H.pylori 
positive was 32.14 years and in H.pylori negative patients was 31.59 years 
and P value was 0.8 and hence was not statistically significant. 
SEX: None of the studies demonstrated any difference in the prevalence of 
H.pylori infected males and females. The P value in our study was 1 and was 
not statistically significant. 
DURATION: Duration of ITP is important in monitoring response to 
treatment of H.pylori. Shorter the duration better is the response.
8
The mean 
85 
 
duration of H.pylori positive patients was 31 months and H.pylori negative 
patients was 28.5 months. P value was 1 and was not significant. 
DYSPEPSIA: Significant association between H.pylori positivity and 
dyspepsia was reported by Michel et al
16
, but not by Stasi et al
8
.In our study 
there was no significant association, P value was 0.38. 
PLATELET COUNT: There were no studies which showed any significant 
association between the initial platelet count and H.pylori positivity.
8, 14 
but 
most of the H.pylori infected ITP patients presented with severe form of ITP 
at the time of diagnosis In our study 14 of 18(77.77%) H.pylori ITP patients 
presented with severe ITP at the time of diagnosis and their platelet counts 
were <30000cells/cu mm and it is statistically significant, P value is 0.003. 
Other parameters like residence, socioeconomic status, bleeding and 
presence of skin rashes were assessed, but were not clinically significant. 
The endoscopic finding of gastritis was also assessed in H.pylori positive 
and negative cases but was not significant 
ASSOCIATION BETWEEN H.PYLORI AND ITP: 
Recently H.pylori has been implicated in a number of autoimmune diseases 
like ITP.
11
.The first association was proved in 1998 by Gasberrini et al
19
. 
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Small study by Emilia et al
14
 (13 positive of 30) also proved significant 
association. 
In our study 18 (36%) were positive out 50 ITP patients. The P value was 
0.048 and hence was statistically significant. So similar to other studies our 
study also proves significant association between H.pylori and ITP.  
 
Observe
d N 
Expecte
d N Residual 
Positive 18 25.0 -7.0 
Negative 32 25.0 7.0 
Total 50   
 
Test Statistics: 
 RUT 
CHI – SQUARE 3.920 
Df 1 
Asymp  significance 0.048 
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Most of the studies in literature have found a high frequency of H.pylori 
infection in patients with ITP and it was observed that in most of them after 
the eradication of H.pylori there was a significant increase in platelet 
count.
12-15
 World this association has been found in 27 other studies. A 
consolidated analysis of these studies shows that 65.7% of ITP patients are 
infected with H.pylori. In contrast some studies from USA
17
 and France 
have reported only a low frequency of H.pylori infection .The possible 
explanation for this could be the low prevalence of H.pylori infection in this 
population. The reason for such discordant reports is uncertain but it might 
reflect the results of studying diverse patient groups, failure to stop 
concomitant treatment and the genetic diversity of H.pylori. 
The frequency of H.pylori association with ITP reflected the prevalence of 
H.pylori in that geographical area. H.pylori positivity was propionate to the 
general population. This explains why most of the reports are from Japan 
and Italy .Successful H.pylori eradication led to good platelet response in 
areas where H.pylori infection rate in ITP patients was higher than in those 
where no association was found.
8
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LIMITATIONS: 
1. Long term follow up not done. 
2. H.pylori positive patients were treated but their platelet response was not 
monitored. 
3. Results need to be confirmed in a larger group of patients and longitudinal 
groups. 
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CONCLUSION: 
 The present study confirms the existence of association between 
H.pylori and ITP (P < 0.05). 
 Our study also showed a significant association between the platelet 
counts at presentation in H.pylori positive ITP patients.  
 There was no significant association with other parameters like sex, 
age, residence, socioeconomic status, bleeding, dyspepsia and 
endoscopy findings. 
 Considering the low costs and non-invasiveness of the diagnostic test 
and the favorable toxicity profile of eradication compared to the 
standard treatment for ITP the detection and eradication of H.pylori 
should be considered in high prevalent areas. The British society of 
Hematology recommends H.pylori eradication and screening as a 
treatment in ITP. 
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ANNEXURES: 
                                           INSTITUTE OF INTERNAL MEDICINE 
                                                 MMC & RGGGH, CHENNAI-3                                                       
                                                                PROFOMA 
 
NAME :                                                                     ADDRESS : 
AGE/SEX : 
OCCUPATION :                                                        PHONE NO. 
COMPLAINTS : 
EASY FATIGUEABILITY : Y/N 
BLEEDING MANIFESTATIONS : GUMS/HEMATURIA/EPISTAXIS 
BRUISING AT INJECTION SITE: Y/N 
BONE PAIN : Y/N 
FEVER : Y/N 
SKIN RASHES : Y/N 
JOINT PAIN : Y/N 
DRUG INTAKE : Y/N 
PAST HISTORY 
DM :                                                                        CAD: 
SHT :                                                                       STROKE/TIA: 
CKD :                                                                       CCF: 
FAMILY H/O BLEEDING DISORDERS: Y/N 
PERSONAL HISTORY  
Smoker : 
Alcoholic : 
GENERAL EXAMINATION 
BP :                                                  PULSE : 
 
WEIGHT :                                         HEIGHT :  
PETECHIAE: 
ECCHYMOSIS: 
BLEEDING SPOTS IN THE BUCCAL MUCOSA:                                      
SYSTEMIC  EXAMINATION :   
CVS:  
RS: 
P/A: 
CNS: 
INVESTIGATIONS : 
CBC: 
DATE      
HB      
TC      
DC      
ESR      
PLATELET      
 
MCV: MCH: MCHC: 
 
PERIPHERAL SMEAR: 
PT: APTT: INR: 
BLOOD GROUP: 
LDH: RETIC COUNT: 
USG ABDOMEN: 
ANA: 
BONE MARROW ASPIRATION: 
HBsAg: 
ANTI-HCV: 
HIV 1 AND 2: 
ENDOSCOPIC BIOPSY AND RAPID UREASE TEST: 
SERIAL 
NO
AGE SEX OCCUPATION SOCIO ECONOMIC STATUS RESIDENCE BLEEDING SKIN RASH DYSPEPSIA PLATELET COUNT ENDOSCOPY FINDING RAPID UREASE TEST BLOOD GROUP DURATION
1 41 F HW LC URBAN YES(G) YES YES 50,000 POSITIVE(AG) NEGATIVE O positive 15
2 16 F STUDENT LC URBAN YES(G) YES NO 10,000 POSITIVE(AG) NEGATIVE B POSITIVE 48
3 21 F HW LC URBAN YES(G,E) YES NO 30,000 NEGATIVE NEGATIVE O positive 5
4 26 F HW LC URBAN YES(G,E) NO NO 31,000 NEGATIVE POSITIVE B POSITIVE 60
5 17 M L UC RURAL YES(G,E) NO YES 20,000 NEGATIVE NEGATIVE O positive 30
6 18 F STUDENT LC URBAN YES(G) NO YES 15,000 NEGATIVE NEGATIVE A POSITIVE 28
7 40 F L LC RURAL YES(M) YES NO 20,000 NEGATIVE POSITIVE O positive 72
8 35 F HW LC URBAN YES(G,H,E) YES NO 10,000 NEGATIVE NEGATIVE O positive 18
9 16 F STUDENT LC URBAN YES(G) NO YES 30,000 NEGATIVE NEGATIVE B POSITIVE 49
10 60 F HW LC URBAN YES(PR) YES NO 22,000 POSITIVE(AG) NEGATIVE O positive 18
11 35 M AD UC URBAN YES(G) YES NO 20,000 POSITIVE(AG) POSITIVE O positive 1
12 40 F HW LC URBAN YES(M) YES NO 15,000 NEGATIVE NEGATIVE B POSITIVE 5
13 30 f HW LC URBAN YES(G,H,E,M) YES NO 10,000 NEGATIVE POSITIVE O positive 8
14 58 F HW LC URBAN YES(M) NO NO 30,000 NEGATIVE NEGATIVE O positive 10
15 42 M FARMER LC RURAL YES(PR) NO NO 52000 POSITIVE(PG) NEGATIVE B POSITIVE 12
16 20 F L LC RURAL YES(G,M) YES NO 20,000 POSITIVE(AG) NEGATIVE O positive 13
17 21 F L UC URBAN YES(G) YES NO 64000 NEGATIVE NEGATIVE O positive 36
18 43 M L LC URBAN NO NO NO 32000 POSITIVE(AG) POSITIVE A POSITIVE 17
19 25 F HW LC URBAN YES(G,H,E) YES NO 10000 POSITIVE(PG) POSITIVE O positive 108
20 24 F HW UC URBAN NO NO YES 45000 NEGATIVE NEGATIVE B POSITIVE 22
21 12 F STUDENT UC URBAN YES(G) YES NO 45000 POSITIVE(PG) POSITIVE O positive 16
22 29 M L LC URBAN YES(G,H,E) YES YES 10000 POSITIVE(PG) NEGATIVE O positive 28
23 25 F HW UC URBAN NO NO NO 34000 NEGATIVE NEGATIVE B POSITIVE 88
24 45 M L LC URBAN YES(E) YES NO 20000 POSITIVE(AG) POSITIVE O positive 34
25 50 F HW LC RURAL YES(G) NO NO 36000 NEGATIVE NEGATIVE A POSITIVE 38
26 18 F L LC URBAN NO YES NO 37000 NEGATIVE NEGATIVE A POSITIVE 17
27 56 F HW LC URBAN YES(G) NO NO 40000 NEGATIVE NEGATIVE O positive 18
28 37 M L LC URBAN YES(G,E) YES NO 20000 NEGATIVE POSITIVE O positive 34
29 30 F HW LC RURAL YES(G,E,M) YES NO 5000 POSITIVE(PG) POSITIVE O positive 2
30 35 F HW LC URBAN YES(G,E) NO NO 20000 NEGATIVE NEGATIVE AB POSITIVE 40
31 50 F HW LC URBAN YES(G) YES NO 32000 NEGATIVE POSITIVE O positive 72
32 21 F HW LC RURAL YES(G,M) YES YES 21000 NEGATIVE POSITIVE O NEGATIVE 6
33 34 F HW LC RURAL YES(G) YES NO 32000 NEGATIVE NEGATIVE A POSITIVE 75
34 30 F HW LC URBAN YES(G) YES NO 15000 POSITIVE(PG) POSITIVE O POSITIVE 42
35 60 F HW LC URBAN YES(G) NO NO 20000 POSITIVE(PG) POSITIVE B NEGATIVE 17
36 22 F HW LC URBAN NO NO YES 62000 POSITIVE(AG) NEGATIVE B POSITIVE 45
37 24 F TEACHER UC URBAN YES(G,M) YES NO 5000 NEGATIVE POSITIVE O POSITIVE 39
38 17 F STUDENT LC RURAL YES(M) NO NO 60000 POSITIVE(AG) NEGATIVE A POSITIVE 15
39 31 M L LC URBAN NO YES NO 12000 POSITIVE(AG) NEGATIVE A POSITIVE 29
40 48 F HW LC URBAN YES(G,M) YES NO 64000 NEGATIVE NEGATIVE AB POSITIVE 60
41 31 F HW LC URBAN YES(G,M) YES YES 20000 NEGATIVE NEGATIVE B NEGATIVE 85
42 37 F HW LC URBAN YES(G,E) YES NO 35000 POSITIVE(PG) NEGATIVE O positive 3
43 27 M L LC URBAN YES(G,H) YES NO 10000 NEGATIVE NEGATIVE o positive 23
SERIAL 
NO
AGE SEX OCCUPATION SOCIO ECONOMIC STATUS RESIDENCE BLEEDING SKIN RASH DYSPEPSIA PLATELET COUNT ENDOSCOPY FINDING RAPID UREASE TEST BLOOD GROUP DURATION
44 16 F STUDENT LC URBAN YES(M) YES YES 5000 POSITIVE(AG) POSITIVE O positive 12
45 40 F HW UC URBAN YES(G,E,M) YES YES 20000 NEGATIVE NEGATIVE B POSITIVE 16
46 28 M L LC RURAL YES(G) NO NO 47000 NEGATIVE NEGATIVE B POSITIVE 6
47 35 F HW LC RURAL YES(G,E,M) YES NO 15000 NEGATIVE POSITIVE O positive 14
48 22 F HW LC URBAN YES(M) NO NO 62000 NEGATIVE NEGATIVE B POSITIVE 12
49 32 M L LC URBAN YES(E) NO YES 44000 POSITIVE(PG) NEGATIVE O positive 7
50 25 F HW LC RURAL YES(E,M) YES YES 9000 POSITIVE(AG) POSITIVE O positive 4
KEYWORDS
M MALE
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HW HOUSE WIFE
L LABOURER
AD ADVOCATE
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